Measures of HbF · people with non‐transfusion‐dependent β‐thalassaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · people with non‐transfusion‐dependent β‐thalassaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with non‐transfusion‐dependent β‐thalassaemia
1 finding from 1 review
Haemoglobin (g/dL) · people with non‐transfusion‐dependent β‐thalassaemia
1 finding from 1 review
Measures of HbF · people with non‐transfusion‐dependent β‐thalassaemia
1 finding from 1 review
QoL · people with non‐transfusion‐dependent β‐thalassaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with non‐transfusion‐dependent β‐thalassaemia
It is very uncertain whether single foetal haemoglobin inducer at any dose or duration changes adverse events compared with usual care or placebo (very low certainty).
1 finding from 1 review
Fatigue relief ( · adults with advanced cancer and cancer‐related fatigue
1 finding from 1 review
Adverse events · adults with advanced cancer and cancer‐related fatigue
1 finding from 1 review
Serious adverse events · adults with advanced cancer and cancer‐related fatigue
1 finding from 1 review
QoL · adults with advanced cancer and cancer‐related fatigue
1 finding from 1 review
Death or major neurodevelopmental disability at 18 to 24 months · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine probably leads to lower death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Death or major neurodevelopmental disability at 18 to 24 months · preterm infants at risk for apnea
Methylxanthine showed no clear difference in death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Death at hospital discharge · preterm infants at risk for apnea
It is very uncertain whether methylxanthine changes death at hospital discharge compared with placebo or control (very low certainty).
1 finding from 1 review
Major neurodevelopmental disability at childhood · preterm infants at risk for apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
a) Cerebral palsy or gross motor disability · preterm infants at risk for apnea
Methylxanthine showed no clear difference in a) Cerebral palsy or gross motor disability compared with placebo or control (moderate certainty).
1 finding from 1 review
Developmental delay at ≥ 18 months · preterm infants at risk for apnea
Methylxanthine showed no clear difference in b) Developmental delay compared with placebo or control (moderate certainty).
1 finding from 1 review
Any apneic episodes · preterm infants at risk for apnea
Methylxanthine may leads to lower any apneic episodes compared with placebo or control (low certainty).
1 finding from 1 review
Positive‐pressure ventilation after institution of treatment · preterm infants at risk for apnea
Methylxanthine showed no clear difference in positive‐pressure ventilation after institution of treatment compared with placebo or control (low certainty).
1 finding from 1 review
Oxygen requirement at 36 weeks' postmenstrual age · preterm infants at risk for apnea
Methylxanthine probably leads to lower supplemental oxygen at 36 weeks' postmenstrual age compared with placebo or control (moderate certainty).
1 finding from 1 review